98.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$97.62
Aprire:
$97.76
Volume 24 ore:
3.34M
Relative Volume:
1.18
Capitalizzazione di mercato:
$17.27B
Reddito:
$381.03M
Utile/perdita netta:
$-1.01B
Rapporto P/E:
-16.51
EPS:
-5.95
Flusso di cassa netto:
$-789.25M
1 W Prestazione:
-6.30%
1M Prestazione:
+37.05%
6M Prestazione:
+40.44%
1 anno Prestazione:
+52.31%
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
INSM
Insmed Inc
|
98.24 | 17.27B | 381.03M | -1.01B | -789.25M | -5.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-13 | Iniziato | Jefferies | Buy |
2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
2024-04-23 | Iniziato | Truist | Buy |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-11-20 | Ripresa | JP Morgan | Overweight |
2023-07-26 | Iniziato | Guggenheim | Buy |
2022-12-09 | Iniziato | Mizuho | Buy |
2022-12-07 | Iniziato | Barclays | Overweight |
2022-11-18 | Iniziato | BofA Securities | Buy |
2022-04-27 | Iniziato | Goldman | Buy |
2021-12-06 | Iniziato | JP Morgan | Overweight |
2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
2021-10-19 | Ripresa | Morgan Stanley | Overweight |
2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2020-12-17 | Iniziato | Berenberg | Buy |
2020-10-12 | Ripresa | Stifel | Buy |
2019-09-03 | Iniziato | Goldman | Buy |
2019-04-09 | Reiterato | H.C. Wainwright | Buy |
2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
2019-01-02 | Iniziato | Canaccord Genuity | Buy |
2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2018-07-23 | Iniziato | Goldman | Neutral |
2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2018-03-21 | Iniziato | Morgan Stanley | Overweight |
2018-01-18 | Iniziato | Credit Suisse | Neutral |
2017-09-05 | Reiterato | Evercore ISI | Outperform |
2017-08-17 | Iniziato | Evercore ISI | Outperform |
2017-07-11 | Iniziato | Robert W. Baird | Outperform |
2016-03-15 | Iniziato | Stifel | Buy |
2015-11-09 | Downgrade | UBS | Buy → Neutral |
2015-10-06 | Reiterato | H.C. Wainwright | Buy |
2015-06-09 | Iniziato | Citigroup | Neutral |
2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Is Insmed Stock Overvalued at $98? - Nasdaq
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed (INSM) Soars After Raising $650 million - MSN
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Insmed Stock Ends Volatile Session Lower, Pauses After Monumental 32% Weekly Surge - Daily Chhattisgarh News
Insmed aims to raise $750M in one of the largest stock offerings this year - Endpoints News
Stocks To Watch: Insmed Sees RS Rating Jump To 93 - MSN
Insmed dips after $750 mln stock sale - TradingView
Insmed (INSM) Secures $750 Million Through Stock Offering - GuruFocus
Insmed is an attractive, but expensive takeout meal - statnews.com
INSM Increases Common Stock Offering to $750M | INSM Stock News - GuruFocus
Insmed Prices $750 Million Common Stock Offering - MarketScreener
Bank of America Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - Defense World
Insmed Raises Massive $750M in Stock Offering to Advance Breakthrough Drug Pipeline - Stock Titan
INSM: Mizuho Raises Price Target for Insmed to $110 | INSM Stock News - GuruFocus
Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr - Nasdaq
Insmed raises $750 million in public offering of common stock By Investing.com - Investing.com Canada
Insmed Announces Pricing of $750 Million Public Offering of Comm - GuruFocus
Insmed raises $750 million in public offering of common stock - Investing.com
Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share - marketscreener.com
Insmed Announces Pricing of $750 Million Public Offering of Common Stock - marketscreener.com
These 10 Stocks Are Flying High - Insider Monkey
Insmed (INSM) Plans $650M Public Offering of Common Stock | INSM - GuruFocus
Insmed's drug for rare lung disease meets main goal in mid-stage trial - MSN
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM) - Yahoo Finance
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed (INSM) Sees Price Target Boost Amid Strong PAH Data | INS - GuruFocus
Insmed (INSM) Price Target Raised to $120 by HC Wainwright & Co. - GuruFocus
Insmed (INSM) Plans $650M Stock Offering, Shares Fall - GuruFocus
Insmed announces $650 million public offering of common stock - Investing.com
Insmed announces $650 million public offering of common stock By Investing.com - Investing.com Canada
Insmed Plans $650 Million Public Offering - marketscreener.com
Insmed announces $650M common stock offering - TipRanks
Insmed Announces Proposed $650 Million Public Offering of Common Stock | INSM Stock News - GuruFocus
Insmed (INSM) Sees Boost with Positive Phase 2b Trial Results | - GuruFocus
Insmed (INSM) Receives Boosted Price Target from Wells Fargo | I - GuruFocus
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Bonstein Sara | Chief Financial Officer |
Jun 23 '25 |
Option Exercise |
19.16 |
47,889 |
917,479 |
151,301 |
Bonstein Sara | Chief Financial Officer |
Jun 23 '25 |
Sale |
101.78 |
57,765 |
5,879,089 |
93,536 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):